Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a €20 million ($21.9 million) financing through the issuance of a Mandatory ...

Chinese pair Hutchmed and Innovent Biologics have announced that the FRUSICA-2 Phase II/III trial of fruquintinib and ...

(Alliance News) - Hutchmed China Ltd on Wednesday hailed results of a clinical trial evaluating its kidney cancer treatment in China, while it reported an annual revenue dive. The Hong Kong-based ...

Hutchmed China, alongside Innovent Biologics, announced on Wednesday that the FRUSICA-2 phase two and three clinical trial ...

Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side ...

The real-time assessment is made possible by integrating Aiosyn’s pathology platform into Pramana’s AI edge compute ...

Among patients with renal cell carcinoma, those with larger tumors may yield the most benefit from SBRT compared with other ...

Momentum Builds Across Programs with Key Data Milestones Expected in 2025Cemacabtagene Ansegedleucel (Cema-Cel): First-Line (1L) Consolidation in ...

PSMA may be a noninvasive biomarker for predicting treatment response in metastatic clear cell renal cell carcinoma (RCC).

Circulating kidney injury molecule-1 (KIM-1) predicts survival outcomes in patients with metastatic renal cell carcinoma (mRCC), even in patients who have coexisting acute kidney injury (AKI) or ...

Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal ...

With the rising adoption of checkpoint inhibitors and combination therapies, BAVENCIO's market growth is driven by expanding indications and strategic partnerships. However, competition from ...